No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
www.handapharma.com.twNo one on the platform currently holds 6620.TWO.
No tracked institution reports a position in 6620.TWO as of their last filing.
No one on the platform has traded 6620.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.2% | — | — | — | ||
| Rev. Growth % | 108.2% | 126.7% | ||||
| Profit Margin % | 43.4% | -140.3% | ||||
| Free Cash Flow Margin % | 13.1% | -122.5% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.7B | -0.5% | $4.45 | $4.45–$4.45 | — | 1 |
| 2027 | $3.0B | +75.2% | $7.67 | $7.67–$7.67 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $0.29 | $0.23 | -21.1% |
| 2026-05-07 | $0.43 | $0.46 | +6.4% |
| 2026-03-12 | $0.43 | $1.12 | +160.5% |
| 2024-03-29 | $5.37 | $0.83 | -84.5% |
| $78.60 |
| +0.38% |
| $19.5B |
| — |
| 4114.TWOSynmosa Biopharma Corporation | $29.35 | +0.00% | $15.8B | — |
| 4147.TWOTaiMed Biologics Inc. | $60.80 | +2.01% | $16.5B | — |
Source: Financial Modeling Prep · peers by sector/industry